Condition
Knee Osteoarthritis
The most-researched human SVF topic, including RCTs and systematic reviews.
Quick summary
- • Multiple RCTs and systematic reviews exist
- • Main reported outcomes are pain and function scores
- • Not established as standard care in general clinical guidelines
Overview
Knee osteoarthritis involves cartilage degeneration with low-grade chronic inflammation. It carries the largest volume of SVF research in this database, from case series through randomized controlled trials.
Mechanisms studied
Studied mechanisms include modulation of the intra-articular inflammatory environment, paracrine signalling, and effects on chondrocytes in laboratory models — none of which directly translates to new cartilage formation in humans.
Human research
Human studies report WOMAC, VAS, and KOOS changes at 6–24 months. Many report pain-score reductions, but effect sizes vary widely and MRI structural findings remain inconsistent.
Systematic reviews
Systematic reviews and meta-analyses generally find symptom outcomes trending in the same direction while noting moderate-to-high risk of bias and calling for larger placebo-controlled RCTs.
Safety
Reported adverse events are mostly local — swelling, pain, or bruising at the harvest and injection sites. Infection and cell-processing quality remain the key risks to monitor.
Evidence limitations
Existing studies are limited by sample size, methodology, and follow-up, and SVF preparation differs substantially between centres, making cross-study comparison difficult.
Related research
- Level ARandomized Controlled Trial
Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial
A multicentre randomized trial in 480 knee osteoarthritis patients comparing SVF, BMAC and umbilical cord MSCs against corticosteroid injection. At 12 months no cell product outperformed the steroid control.
- 2023
- United States
- n = 480
- Level AMeta-analysis
Intra-articular Injection of Autologous Adipose-Derived Stem Cells or Stromal Vascular Fractions: Are They Effective for Patients With Knee Osteoarthritis? A Systematic Review With Meta-analysis of Randomized Controlled Trials
Pooled five RCTs comparing ADSC/SVF injection with placebo or hyaluronic acid, finding significant pain and function improvement at 6 and 12 months.
- 2023
- South Korea
- Level AMeta-analysis
Rapid-acting pain relief in knee osteoarthritis: autologous-cultured adipose-derived mesenchymal stem cells outperform stromal vascular fraction: a systematic review and meta-analysis
Analysed 31 studies with 1,406 patients: cultured ADMSCs reduced pain from month 3, whereas SVF reached significance only at 12 months.
- 2024
- South Korea
- n = 1406
- Level BMeta-analysis
Clinical Efficacy of Bone Marrow Aspirate Concentrate Versus Stromal Vascular Fraction Injection in Patients With Knee Osteoarthritis: A Systematic Review and Meta-analysis
Synthesised clinical studies of a single intra-articular BMAC or SVF injection to compare effect sizes for pain and function.
- 2022
- United States
- Level BSystematic Review
Stromal Vascular Fraction Therapy for Knee Osteoarthritis: A Systematic Review
Screened 172 articles and included 22; most reported safety and improved clinical outcomes, but designs varied widely.
- 2023
- Russia / Italy
- Level CSystematic Review
Limited evidence for adipose-derived stem cell therapy on the treatment of osteoarthritis
A systematic review of 16 studies (14 knee, 1 ankle, 1 multiple joints): all reported clinical improvement, but preparation methods and outcome reporting were inconsistent.
- 2018
- United States
- Level CProspective Study
The influence of adipose-derived stromal vascular fraction cells on the treatment of knee osteoarthritis
Studied 57 patients receiving a single intra-articular injection of 2.5 × 10⁷ SVF cells with at least 12 months of follow-up.
- 2020
- Japan
- n = 57
- Level DRetrospective Study
A Retrospective Study of Stromal Vascular Fraction Cell Therapy for Osteoarthritis
Chart review of 350 knee and hip osteoarthritis patients treated with autologous SVF between 2015 and 2018, reporting the proportion with improved pain and mobility.
- 2020
- Slovakia
- n = 350
Clinical trials
NCT05123456
Intra-articular SVF Injection in Moderate Knee Osteoarthritis
Mahidol University · Thailand · Phase 2
Frequently asked questions
- Does SVF cure knee osteoarthritis?
- No. Current research does not show that SVF cures knee osteoarthritis; reported outcomes are symptom changes over limited follow-up.
- How does SVF differ from PRP in the knee?
- PRP is a platelet-derived product while SVF is a mixed cell population from adipose tissue. Direct comparative research is too limited to declare one superior.
Last updated: 2026-06-18 · arisa-w